A298380 Stock Overview
A biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
ABL Bio Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩37,550.00 |
| 52 Week High | ₩47,250.00 |
| 52 Week Low | ₩21,200.00 |
| Beta | 0.91 |
| 1 Month Change | -19.94% |
| 3 Month Change | 42.23% |
| 1 Year Change | 43.32% |
| 3 Year Change | 36.79% |
| 5 Year Change | 153.72% |
| Change since IPO | 175.09% |
Recent News & Updates
Some Confidence Is Lacking In ABL Bio Inc. (KOSDAQ:298380) As Shares Slide 30%
Nov 20
Is ABL Bio (KOSDAQ:298380) Using Too Much Debt?
May 29Recent updates
Some Confidence Is Lacking In ABL Bio Inc. (KOSDAQ:298380) As Shares Slide 30%
Nov 20Is ABL Bio (KOSDAQ:298380) Using Too Much Debt?
May 29Is ABL Bio (KOSDAQ:298380) Weighed On By Its Debt Load?
Feb 26We Think ABL Bio (KOSDAQ:298380) Can Afford To Drive Business Growth
Mar 31Should ABL Bio (KOSDAQ:298380) Be Disappointed With Their 33% Profit?
Jan 20
Companies Like ABL Bio (KOSDAQ:298380) Are In A Position To Invest In Growth
Dec 16Shareholder Returns
| A298380 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 1.6% | 3.9% | 2.1% |
| 1Y | 43.3% | 23.0% | -5.2% |
Return vs Industry: A298380 exceeded the KR Biotechs industry which returned 23% over the past year.
Return vs Market: A298380 exceeded the KR Market which returned -5.2% over the past year.
Price Volatility
| A298380 volatility | |
|---|---|
| A298380 Average Weekly Movement | 10.6% |
| Biotechs Industry Average Movement | 7.2% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in KR Market | 11.8% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A298380's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A298380's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Sang Hoon Lee | www.ablbio.com |
ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline drugs include ABL001, cancer immunotherapy, ADC, and ABL301. ABL Bio Inc.is headquartered in Seongnam-si, South Korea.
ABL Bio Inc. Fundamentals Summary
| A298380 fundamental statistics | |
|---|---|
| Market cap | ₩1.96t |
| Earnings (TTM) | -₩55.53b |
| Revenue (TTM) | ₩33.40b |
54.3x
P/S Ratio-32.6x
P/E RatioIs A298380 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A298380 income statement (TTM) | |
|---|---|
| Revenue | ₩33.40b |
| Cost of Revenue | ₩61.26m |
| Gross Profit | ₩33.34b |
| Other Expenses | ₩88.87b |
| Earnings | -₩55.53b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.15k |
| Gross Margin | 99.82% |
| Net Profit Margin | -166.24% |
| Debt/Equity Ratio | 25.7% |
How did A298380 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/20 08:56 |
| End of Day Share Price | 2025/03/20 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ABL Bio Inc. is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jisoo Lee | DAOL Investment & Securities Co., Ltd. |
| Haesoon Kwon | Eugene Investment & Securities Co Ltd. |
| Jihoon Shin | LS Securities Co., Ltd. |